colfosceril

colfosceril

 [kol-fos´ĕ-ril]
a synthetic pulmonary surfactant used as the palmitate ester in combination with tyloxapol and an alcohol in prophylaxis and treatment of neonatal respiratory distress syndrome; instilled into the endotracheal tube for intratracheal administration.

colfosceril

/col·fos·e·ril/ (kol-fos´ĕ-ril) a synthetic pulmonary surfactant used as the palmitate ester, in combination with cetyl alcohol and tyloxapol, in the prophylaxis and treatment of neonatal respiratory distress syndrome.

colfosceril

[kolfos′eril]
a synthetic pulmonary surfactant used as the palmitate ester in combination with tyloxapol and as an alcohol in prophylaxis and treatment of neonatal respiratory distress syndrome, instilled into the endotracheal tube for intratracheal administration.
References in periodicals archive ?
In the study, the infants were treated with lucinactant (Surfaxin), colfosceril palmitate (Exosurf), or beractant (Survanta) within 30 minutes of birth.
In addition to colfosceril and beractant, the other two FDA-approved surfactants are poractant alpha (Curosurf) and calfactant (Infasurf).
One of the first available protein-free, artificial surfactant preparations was Exosurf, or colfosceril palmitate plus cetyl alcohol and tyloxapol.
Lucinactant Comparison Trial to Colfosceril palmitate and Beractant
In 2005, Moya et al published a large prospective randomized clinical trial that reported a higher RDS mortality rate for colfosceril palmitate (a synthetic surfactant) and beractant (a natural surfactant) than for lucinactant.
One third of the patients were in 2 cells (lucinactant >1,000 g and colfosceril >1,000 g).
It is a natural bovine lung extract mixed with colfosceril palmitate (DPPC), palmitic acid, and tripalmitin.